Pfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in ChinaPfizer has paid $200 million to buy 9.9% of Hong Kong-listed cancer biotech CStone, beginning a strategic collaboration Share XPfizer picks up rights to CStone’s cancer immunotherapy sugemalimab in Chinahttps://pharmaphorum.com/news/pfizer-picks-up-rights-to-cstones-cancer-immunotherapy-sugemalimab-in-china/
Blank cheque company merger creates cancer specialist VinceraLifeSci Acquisition – a so-called ‘blank cheque’ company – has announced a $60 million merger with Vincera Pharma Share XBlank cheque company merger creates cancer specialist Vincerahttps://pharmaphorum.com/news/blank-cheque-company-merger-creates-cancer-specialist-vincera/
Israel’s NeuroHelp to trial AI device that predicts epileptic seizuresNeuroHelp, a spin-off from Israel’s Ben-Gurion University of the Negev, has developed what it claims to be the Share XIsrael’s NeuroHelp to trial AI device that predicts epileptic seizureshttps://pharmaphorum.com/news/israels-neurohelp-to-trial-ai-device-that-predicts-epileptic-seizures/
False positives with Apple Watch could tie up health resourcesApple’s latest ad campaign for its Apple Watch makes much of its ability to monitor health functions – Share XFalse positives with Apple Watch could tie up health resourceshttps://pharmaphorum.com/news/false-positives-with-apple-watch-could-tie-up-health-resources/
Junshi plans filings after toripalimab hits target in upper throat cancerChina’s Junshi Biosciences has said it plans filings for a new cancer immunotherapy after its toripalimab outperformed standard Share XJunshi plans filings after toripalimab hits target in upper throat cancerhttps://pharmaphorum.com/news/junshi-plans-filings-after-toripalimab-hits-target-in-upper-throat-cancer/
FDA slams brakes on Inovio’s final-stage COVID-19 vaccine trialsInovio Pharma’s plan to start pivotal testing of its COVID-19 vaccine has been delayed by FDA requests for Share XFDA slams brakes on Inovio’s final-stage COVID-19 vaccine trialshttps://pharmaphorum.com/news/fda-slams-brakes-on-inovio-final-stage-covid-19-vaccine-trials/
FDA fast-tracks AbbVie’s spinal injury drugThe FDA has fast tracked development of AbbVie’s potential spinal injury drug, elezanumab, a process that will be Share XFDA fast-tracks AbbVie’s spinal injury drughttps://pharmaphorum.com/news/fda-fast-tracks-abbvies-spinal-injury-drug/
UK has no plans to buy rapid COVID-19 test favoured by US and WHOThe US and some of the world’s poorest countries may get a low-cost and rapid COVID-19 test ahead Share XUK has no plans to buy rapid COVID-19 test favoured by US and WHOhttps://pharmaphorum.com/news/uk-has-no-plans-to-buy-rapid-covid-19-test-favoured-by-us-and-who/
UK pledges £571m to equitable COVID-19 vaccine access schemeUK Prime Minister Boris Johnson has told the UN General Assembly that the UK will donate £571 million Share XUK pledges £571m to equitable COVID-19 vaccine access schemehttps://pharmaphorum.com/news/uk-pledges-571m-to-equitable-covid-19-vaccine-access/
FDA launches Digital Health Center of ExcellenceThe FDA has launched its Digital Health Center of Excellence (DHCoE), as the agency continues with its commitment Share XFDA launches Digital Health Center of Excellencehttps://pharmaphorum.com/news/fda-launches-digital-health-center-of-excellence/
Scientists urge Pfizer to delay COVID-19 vaccine filingA group of leading scientists have urged Pfizer to wait until at least late November before asking for Share XScientists urge Pfizer to delay COVID-19 vaccine filinghttps://pharmaphorum.com/news/scientists-urge-pfizer-to-delay-covid-19-vaccine-filing/
Valirx eyes partnerships as first VAL201 study hits the markShares in UK biotech Valirx were up sharpy this morning after its lead drug VAL201 showed evidence of Share XValirx eyes partnerships as first VAL201 study hits the markhttps://pharmaphorum.com/news/valirx-eyes-partnerships-as-first-val201-study-hits-the-mark/
Galecto raises $64m to finance EU filing for inhaled IPF drugPrivately-held biotech Galecto has raised $64m with an equity funding round to further research into treatments for drugs Share XGalecto raises $64m to finance EU filing for inhaled IPF drughttps://pharmaphorum.com/news/galecto-raises-64m-to-finance-eu-filing-for-inhaled-ipf-drug/
Takeda’s bleeding disorder drug Veyvondi backed for NHS useNHS England has recommended that patients with von Willebrand disease (VWD) be treated with Takeda’s Veyvondi, making it Share XTakeda’s bleeding disorder drug Veyvondi backed for NHS usehttps://pharmaphorum.com/news/takedas-bleeding-disorder-drug-veyvondi-backed-for-nhs-use/
Novavax begins late-stage trial of COVID-19 vaccine in the UKNovavax has begun a late-stage trial of its experimental COVID-19 vaccine in the UK, which could support filings Share XNovavax begins late-stage trial of COVID-19 vaccine in the UKhttps://pharmaphorum.com/news/novavax-begins-late-stage-trial-of-covid-19-vaccine-in-the-uk/
Gilead’s rheumatoid arthritis pill approved in JapanGilead has scored a major approval for its troubled rheumatoid arthritis pill filgotinib, after regulators in Japan granted Share XGilead’s rheumatoid arthritis pill approved in Japanhttps://pharmaphorum.com/news/gileads-rheumatoid-arthritis-pill-approved-in-japan/
FDA fast-tracks Leap’s gastric cancer immunotherapyLeap Therapeutics will get a swift FDA review for its lead drug DKN-01 for a form of gastric Share XFDA fast-tracks Leap’s gastric cancer immunotherapyhttps://pharmaphorum.com/news/fda-fast-tracks-leaps-gastric-cancer-immunotherapy/
New data reinforce Keytruda’s dominance in first-line lung cancerFive-year data with Merck & Co’s Keytruda showing that it doubles survival should help the drug fend off Share XNew data reinforce Keytruda’s dominance in first-line lung cancerhttps://pharmaphorum.com/news/new-data-reinforce-keytrudas-dominance-in-first-line-lung-cancer/
P360 Announces Design Your Own Swittons Contest Share XP360 Announces Design Your Own Swittons Contesthttps://pharmaphorum.com/partner-content/p360-announces-design-your-own-swittons-contest/
Innovate UK funding for new precision cancer treatment technology Share XInnovate UK funding for new precision cancer treatment technologyhttps://pharmaphorum.com/partner-content/innovate-uk-funding-for-new-precision-cancer-treatment-technology/
Leading Microbiologists to meet at SMi’s 10th Annual Pharmaceutical Microbiology Conference Share XLeading Microbiologists to meet at SMi’s 10th Annual Pharmaceutical Microbiology Conferencehttps://pharmaphorum.com/partner-content/leading-microbiologists-to-meet-at-smis-10th-annual-pharmaceutical-microbiology-conference/
P360 Adds Advanced Artificial Intelligence Capabilities to its Sales Enablement Platform BirdzAI Share XP360 Adds Advanced Artificial Intelligence Capabilities to its Sales Enablement Platform BirdzAIhttps://pharmaphorum.com/partner-content/p360-adds-advanced-artificial-intelligence-capabilities-to-its-sales-enablement-platform-birdzai/
Prescient Announces Recent Appointments to the Senior Advisory Team Share XPrescient Announces Recent Appointments to the Senior Advisory Teamhttps://pharmaphorum.com/partner-content/prescient-announces-recent-appointments-to-the-senior-advisory-team/
Prescient Intelligence & Insight Announces Recent Appointments to the Senior Team Share XPrescient Intelligence & Insight Announces Recent Appointments to the Senior Teamhttps://pharmaphorum.com/partner-content/prescient-intelligence-insight-announces-recent-appointments-to-the-senior-team-2/
